



September 2021

Dear Doctor,

## New PBS indication for VIMPAT® (lacosamide) Effective 1 September, 2021

**Now PBS reimbursed for:** Add-on therapy in the treatment of primary generalised tonic-clonic seizures (PGTCS) in patients with idiopathic generalised epilepsy (IGE) aged 4 years and older<sup>1</sup>

UCB Australia is pleased to announce the new PBS listing for Vimpat® (lacosamide) as add-on therapy in the treatment of PGTCS in patients with IGE aged 4 years and older, effective 1 September, 2021.<sup>1</sup>

**PBS Criteria:** 'Add-on' Vimpat® is now an option for your patients (aged 4 years and older) with IGE who are experiencing PGTCS, who have failed two ASMs and are currently taking one ASM<sup>1</sup>

### Authority required streamlined codes for PGTCS:

	Initial and Continuing treatment
50mg – 14 tab* or 56 tab <sup>†</sup>	12092
100mg and 150mg – 14 tab*	12225
100mg, 150mg and 200mg – 56 tab	12092
10mg/mL oral solution – 200mL	12092

\*For dose titration purposes only. <sup>†</sup>4 x 14 tabs, 50mg pack.

For further information or to request Vimpat® samples, please contact your local UCB representative or the UCB medical information department on +61 (3) 9828 1800, option (3).

Yours sincerely,

Selina Clifford  
Head of Neurology – Australia  
UCB Australia



**PBS INFORMATION: Partial seizures and Primary generalised tonic-clonic seizures.**  
**Tablets and Oral solution:** Authority Required (STREAMLINED). Refer to the PBS schedule for full authority information. **Injection:** This product is not listed on the PBS.

**Please review Product Information before prescribing.**

Product Information can be accessed at

[www.ucbpharma.com.au/Vimpat-oral](http://www.ucbpharma.com.au/Vimpat-oral) | [www.ucbpharma.com.au/Vimpat-IV](http://www.ucbpharma.com.au/Vimpat-IV)

**Vimpat® (lacosamide) 50, 100, 150, 200mg oral tablets, 10mg/mL oral solution, 10mg/mL IV solution. Minimum Product Information:**

**Approved Indication:** Vimpat tablets are indicated as monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older; as add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older; and as add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older. Vimpat injection is indicated when oral administration is temporarily not feasible. **Contraindications:** Hypersensitivity to any components. Known second- or third-degree atrioventricular (AV) block. **Precautions:** Vimpat® may cause dizziness or blurred vision. Driving or operating hazardous machinery. Dose dependent prolongations in PR interval have been observed. Use with caution in patients with conduction problems or with severe cardiac disease. May predispose patients with diabetic neuropathy and/or cardiovascular disease to atrial arrhythmias. Abnormalities in liver function tests have been observed. AEDs, including lacosamide, increase the risk of suicidal thoughts or behaviour. Patients, caregivers, and families should be advised of the need to be alert for the emergence of worsening of the signs and symptoms of depression, any unusual changes in mood or behaviour, or the emergence of suicidal thoughts, behaviour, or thoughts about self-harm. Elderly. Pregnancy (Category B3), children under 4 years. Do not withdraw abruptly. Oral solution use in people with phenylketonuria. **Adverse Effects:** Very common: dizziness, headache, nausea and diplopia. Common: confusional state, insomnia, hypoesthesia, dysarthria, disturbance in attention, paraesthesia, tinnitus, dyspepsia, dry mouth, diarrhoea, irritability, feeling drunk, muscle spasms, contusion, depression, balance disorder, coordination abnormal, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, vision blurred, vertigo, vomiting, constipation, flatulence, pruritus, gait disturbance, asthenia, fatigue, fall, and skin laceration. **Dosage and method of use:** Vimpat may be initiated with either oral or IV administration as monotherapy or add-on therapy. In adults, a starting dose of 100 mg twice daily (monotherapy) or 50 mg twice daily (add-on therapy) increased to an initial therapeutic dose of 100 mg twice daily after one week is recommended. Depending on response and tolerability, the dose may be increased by 50 mg twice daily every week, to a maximum recommended daily dose of 300 mg twice daily (monotherapy), or 200 mg twice daily (add-on therapy). If Vimpat® has to be discontinued, gradual withdrawal is recommended. For detailed dose and method of administration for each indication and age/weight group including adolescents and children, please refer to full PI. For more details see full PI. Date first included on ARTG: 31st July 2012. Date of most recent amendment: 27th April 2021.

**Abbreviations:** **PGTCS**, primary generalised tonic-clonic seizure; **ASM**, anti-seizure medication; **IGE**, idiopathic generalised epilepsy

**Reference: 1.** PBS indication: <https://www.pbs.gov.au/pbs/search?term=lacosamide>

This communication has been sent to you by UCB Australia Pty Ltd (“UCB”), based on information collected by IQVIA Solutions Australia Pty Ltd, provider of Customer Relationship Management products and services to life sciences companies in Australia. UCB and IQVIA comply with the Australian Privacy Act 1988 (Cth) and the underlining Australian Privacy Principles. Should you wish to have more information about IQVIA please visit the following website: <https://www.iqvia.com/about-us/privacy/privacy-policy>.

If you do not wish to receive further communications from UCB, please email: [dataprivacy.au@ucb.com](mailto:dataprivacy.au@ucb.com) or tick the relevant box below then fax back this page to UCB on **03 9828 1860**. Thank you, I do NOT want to receive communications as outlined above from UCB via  
 Mail  Fax  Email

Name: .....

Signature: ..... Date: DD / MM / YYYY